首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3131篇
  免费   231篇
  国内免费   77篇
耳鼻咽喉   16篇
儿科学   67篇
妇产科学   64篇
基础医学   378篇
口腔科学   55篇
临床医学   303篇
内科学   684篇
皮肤病学   36篇
神经病学   258篇
特种医学   291篇
外科学   555篇
综合类   81篇
预防医学   142篇
眼科学   55篇
药学   184篇
中国医学   12篇
肿瘤学   258篇
  2023年   16篇
  2022年   7篇
  2021年   47篇
  2020年   28篇
  2019年   40篇
  2018年   63篇
  2017年   41篇
  2016年   60篇
  2015年   108篇
  2014年   112篇
  2013年   192篇
  2012年   207篇
  2011年   156篇
  2010年   100篇
  2009年   121篇
  2008年   166篇
  2007年   206篇
  2006年   167篇
  2005年   177篇
  2004年   157篇
  2003年   118篇
  2002年   115篇
  2001年   100篇
  2000年   85篇
  1999年   71篇
  1998年   42篇
  1997年   56篇
  1996年   36篇
  1995年   43篇
  1994年   28篇
  1993年   28篇
  1992年   56篇
  1991年   34篇
  1990年   36篇
  1989年   48篇
  1988年   50篇
  1987年   40篇
  1986年   33篇
  1985年   27篇
  1984年   18篇
  1983年   21篇
  1982年   19篇
  1981年   10篇
  1980年   12篇
  1979年   8篇
  1977年   8篇
  1976年   20篇
  1975年   7篇
  1974年   8篇
  1968年   9篇
排序方式: 共有3439条查询结果,搜索用时 15 毫秒
1.
For advanced and metastatic urothelial carcinomas (UCs), platinum (preferably cisplatin)‐based chemotherapy has been the standard treatment for many years. However, many patients are ineligible for cisplatin‐based chemotherapy because of poor performance status and/or other age‐related conditions. At the other end of the spectrum, patients with localized non‐muscle–invasive bladder cancer who are unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) treatment often face radical cystectomy as the only option. In recent years, the application of immunotherapy in the form of immune‐checkpoint inhibitors has provided viable alternatives in the second‐line postplatinum and first‐line cisplatin‐ineligible settings. Recent and ongoing clinical trials are also assessing the safety and efficacy of immunotherapy for neoadjuvant and adjuvant uses before/after cystectomy, for BCG‐unresponsive cases, and for combination treatments that include the newer indoleamine 2,3‐dioxygenase‐1 inhibitors and/or BCG. This review summarizes recent developments in immunotherapy for UCs.  相似文献   
2.
3.
氟喹诺酮类药物不良反应168例分析   总被引:12,自引:0,他引:12  
施玲玲 《医学争鸣》2005,26(6):531-531
0 引言 随着氟喹诺酮类药物在临床的广泛应用,有关其应用所致不良反应的报道也日趋增多,我们通过对1990/2003年我院氟喹诺酮类药物不良反应情况报告如下,供临床参考。  相似文献   
4.
5.
Elucidating the mechanism of liver tumor growth and metastasis after hepatic ischemia-reperfusion (I/R) injury of a small liver remnant will lay the foundation for the development of therapeutic strategies to target small liver remnant injury, and will reduce the likelihood of tumor recurrence after major hepatectomy or liver transplantation for liver cancer patients. In the current study, we aimed to investigate the effect of hepatic I/R injury of a small liver remnant on liver tumor development and metastases, and to explore the precise molecular mechanisms. A rat liver tumor model that underwent partial hepatic I/R injury with or without major hepatectomy was investigated. Liver tumor growth and metastases were compared among the groups with different surgical stress. An orthotopic liver tumor nude mice model was used to further confirm the invasiveness of the tumor cells from the above rat liver tumor model. Significant tumor growth and intrahepatic metastasis (5 of 6 vs. 0 of 6, P=0.015), and lung metastasis (5 of 6 vs. 0 of 6, P=0.015) were found in rats undergoing I/R and major hepatectomy compared with the control group, and was accompanied by upregulation of mRNA levels for Cdc42, ROCK (Rho kinase), and vascular endothelial growth factor, as well as activation of hepatic stellate cells. Most of the nude mice implanted with liver tumor from rats under I/R injury and major hepatectomy developed intrahepatic and lung metastases. In conclusion, hepatic I/R injury of a small liver remnant exacerbated liver tumor growth and metastasis by marked activation of cell adhesion, invasion, and angiogenesis pathways.  相似文献   
6.
7.
Head injury in children causes special concern in most communities. From 1989 to 1994, 2,785 children younger than 16 years old were admitted to our neurosurgical service because of head injury. Fall from a height was the major cause of head injury leading to admission in infants and children in preschool age groups, whereas traffic-related or bicycle-related accidents were more likely to be the cause of head injury for those aged 11–15 years. In all age groups there was a male preponderance. The overall mortality was 0.6%. Traffic-ralated accidents caused more severe injury and accounted for 67% of all fatalities. For patients under 6 years old, about 40% of head injuries occurred at home. Preventive measures for pediatric head injury in Hong Kong are suggested.  相似文献   
8.
Factors influencing women to undergo screening mammography   总被引:2,自引:0,他引:2  
  相似文献   
9.
10.
Angioedema of the oropharynx and hypopharynx due to oral angiotensin-converting enzyme (ACE) inhibitors is a potentially life-threatening event and has not been well described in the radiology literature. A retrospective review of the clinical and radiologic findings in three patients with angioedema due to ACE inhibitor use was performed.Our subgroup of patients treated with ACE inhibitors presented with varying degrees of dysphagia, dyspnea, and facial swelling. Plain radiographic findings included enlargement of the epiglottis, aryepiglottic folds, and prevertebral and submental soft tissue. Computed tomography confirmed extensive retropharyngeal and subcutaneous edema. Clinical symptoms resolved in each case in 24–48 hours with cessation of the ACE inhibitor and concomitant steriod therapy.Our cases demonstrate the typical clinical and radiographic presentation of neck angioedema in the setting of ACE inhibitor use. As ACE inhibitors are increasingly being used as first-line agents in the treatment of hypertension, we caution that neck angioedema may be encountered with increased frequency in adults. Early recognition and immediate intervention result in rapid resolution of this potentially life-threatening event.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号